AR and prostate cancer: Using scWGS, androgen receptor (AR) gene positive or negative prostate cancer CTC subpopulations were identified during the period of androgen deprivation therapy (ADT); CNV evolution reflecting clinical response and disease progression was also observed in CTCs [47].